Takeda Establishes "Takeda Global Advisory Board"

Osaka, Japan, June 23, 2009 --- Takeda Pharmaceutical Company Limited (“Takeda”) today announced the establishment of the Takeda Global Advisory Board (“TGAB”) as part of its vision to become a global pharmaceutical company with strong corporate governance.

By incorporating both members of Takeda’s current executive management as well as four external Advisors with executive level experience at global pharmaceutical companies, the TGAB will discuss and provide the company with valuable guidance on a variety of managerial topics, including innovative medical technologies under the rapidly changing environment surrounding the pharmaceutical industry.

“Takeda is making meaningful changes in its governance through the establishment of Takeda Global Advisory Board and the inclusion of external Advisors,” said Yasuchika Hasegawa, President, Takeda Pharmaceutical Company Limited. “By leveraging the expertise of our external industry leaders, Takeda looks forward to continuing creating and marketing novel pharmaceutical products that meet the needs of patients globally.”

External Members of the Takeda Global Advisory Board (in alphabetical order):

• •Ms. Karen Katen, former Vice Chairman of Pfizer Inc. and currently Senior Advisor for Essex Woodlands Health Ventures
• •Dr. Frank Morich, former CEO of Bayer HealthCare and currently CEO of NOXXON Pharma
• •Mr. Sidney Taurel, former Chairman and CEO of Eli Lilly & Co. and currently Chairman Emeritus of Eli Lilly & Co.
• •Dr. Tadataka Yamada, former chairman of Research and Development and member of the Board of Directors at GlaxoSmithKline and currently President of the Global Health Program at the Bill & Melinda Gates Foundation

###

Profiles of External Members of Takeda Global Advisory Board

Karen Katen, MBA

Frank Morich, MD, PhD

Sidney Taurel, MBA

Tadataka Yamada, MD